Literature DB >> 32843411

Vasospasm induced myocardial ischaemia secondary to sumatriptan use.

Kenneth Okonkwo1, Utkarsh Ojha2.   

Abstract

Certain medications have been implicated in causing acute myocardial infarctions (AMI). Sumatriptan, a medication usually prescribed for acute migraine and cluster headaches has been documented as potentially causing coronary vasospasm, thereby leading to MI. This is usually seen in patients with strong risk factors for coronary artery disease (CAD) or in those with established CAD. Most cases thus far have been reported in patients using the subcutaneous preparation of sumatriptan. Here, we present a case of a patient without prior risk factors for CAD and angiographically unremarkable coronary arteries who presented with evidence of an AMI after oral sumatriptan use for migraines. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular medicine; ischaemic heart disease; pharmacology and therapeutics

Mesh:

Substances:

Year:  2020        PMID: 32843411      PMCID: PMC7449594          DOI: 10.1136/bcr-2020-235387

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Fatal cardiac arrhythmia after oral sumatriptan.

Authors:  K Laine; T Raasakka; J Mäntynen; P Saukko
Journal:  Headache       Date:  1999 Jul-Aug       Impact factor: 5.887

2.  Treatment of migraine attacks with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 3.  Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature.

Authors:  J P Ottervanger; J H Wilson; B H Stricker
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina.

Authors:  Gaetano Antonio Lanza; Alfonso Sestito; Gregory Angelo Sgueglia; Fabio Infusino; Mario Manolfi; Filippo Crea; Attilio Maseri
Journal:  Int J Cardiol       Date:  2006-08-04       Impact factor: 4.164

5.  Unstable angina pectoris associated with Imitrex therapy.

Authors:  M Walton-Shirley; K Flowers; J H Whiteside
Journal:  Cathet Cardiovasc Diagn       Date:  1995-02

6.  5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation.

Authors:  H E Connor; W Feniuk; P P Humphrey
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

7.  Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.

Authors:  P D MacIntyre; B Bhargava; K J Hogg; J D Gemmill; W S Hillis
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

8.  Vasospasm-induced myocardial infarction with sumatriptan.

Authors:  L Mueller; R M Gallagher; C A Ciervo
Journal:  Headache       Date:  1996-05       Impact factor: 5.887

9.  Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association.

Authors:  Yusuke Takagi; Jun Takahashi; Satoshi Yasuda; Satoshi Miyata; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin-Ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
Journal:  J Am Coll Cardiol       Date:  2013-07-31       Impact factor: 24.094

10.  Cardiac arrest following use of sumatriptan.

Authors:  K M Kelly
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.